2015
DOI: 10.1002/jps.24385
|View full text |Cite
|
Sign up to set email alerts
|

Preparation and In Vitro/In Vivo Evaluation of Cyclosporin A-Loaded Nanodecorated Ocular Implants for Subconjunctival Application

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
21
0
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
4
2

Relationship

2
4

Authors

Journals

citations
Cited by 42 publications
(23 citation statements)
references
References 27 publications
1
21
0
1
Order By: Relevance
“…Parallel copper electrodes in 1.8 cm distance from each other were used as a collector. In order to obtain PU nanofibers with aligned and smooth morphology, we optimized the electrospinning parameters such as polymer concentration, the distance between needle and collector, applied voltage and flow rate . Electrospinning solution was prepared by dissolving PU in tetrahidrofurano/dimethylformamide (60:40 [v/v]) solvent mixture and making 8% (w/v) concentration of PU.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Parallel copper electrodes in 1.8 cm distance from each other were used as a collector. In order to obtain PU nanofibers with aligned and smooth morphology, we optimized the electrospinning parameters such as polymer concentration, the distance between needle and collector, applied voltage and flow rate . Electrospinning solution was prepared by dissolving PU in tetrahidrofurano/dimethylformamide (60:40 [v/v]) solvent mixture and making 8% (w/v) concentration of PU.…”
Section: Methodsmentioning
confidence: 99%
“…In order to obtain PU nanofibers with aligned and smooth morphology, we optimized the electrospinning parameters such as polymer concentration, the distance between needle and collector, applied voltage and flow rate. [22][23][24][25][26][27] Electrospinning solution was prepared by dissolving PU in tetrahidrofurano/dimethylformamide (60:40 [v/v]) solvent mixture and making 8% (w/v) concentration of PU. Polymer solutions were placed in a glass syringe (5 mL) bearing metallic capillary (0.41 mm i.d.)…”
Section: Preparation Of Aligned Pu Nanofiber Scaffoldsmentioning
confidence: 99%
“…Another cyclosporine A implant study for LX201 employed subconjunctival implantation that would not affect neovascularization following keratoplasty (Bock et al 2014). It was also reported that cyclosporine A-loaded PLGA nanoparticles and poly[e-caprolactone] (PCL) subconjunctival implants were prepared for dry eye syndrome treatment, and they were able to extend the drug release up to 2 months and provided faster healing in dry eye-induced mice (Pehlivan et al 2015). Pfizer Inc. collaborated on a PLGA subconjunctival insert for sustained-release latanoprost for glaucoma treatment; however, the phase I/IIa (NCT01180062) study was terminated due to inadequate supply of inserts.…”
Section: Ocular Inserts and Implants For Anterior Segment Diseasesmentioning
confidence: 99%
“…In a recent study, PAMAM dendrimers with anionic and cationic charges were investigated for retinal dexamethasone delivery via topical and subconjunctival applications. It was reported that these systems were able to improve corneal and scleral permeability and provide higher ocular bioavailability; however, drug loading in these systems was limited (Yavuz et al 2015). PAMAM-triamcinolone acetonide conjugates with 21% drug loading were also prepared, and cell culture studies indicated increased anti-inflammatory activity of triamcinolone acetonide (Kambhampati et al 2015).…”
Section: Colloidal Dosage Forms For Posterior Segment Drug Deliverymentioning
confidence: 99%
“…In this study, CsA nanoparticles-loaded extended release biodegradable implant and fiber implant formulations have been developed and two formulations were selected for in vivo applications based on in vitro characterization and in vitro release studies which were reported previously (Pehlivan et al, 2015). Selected formulations were implanted subconjunctivally to DES-induced mice model to evaluate the tissue CsA distribution following implantation and efficacy of the formulations.…”
Section: Introductionmentioning
confidence: 99%